ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "The efficacy and safety of aspirin-ticagrelor vs. aspirin-clopidogrel in ischemic stroke patients with cerebral artery stenting"
Episode Synopsis
The efficacy and safety of aspirin-ticagrelor vs. aspirin-clopidogrel in ischemic stroke patients with
cerebral artery stenting
Clin Neurol Neurosurg . 2024 Mar 3:239:108229.
Abstract
Objective: First, the efficacy and safety of
aspirin-ticagrelor after cerebral artery stenting in ischemic stroke patients is controversial. Second, there is a gap in the research on guiding two
antiplatelet therapy after stenting based on the CYP2C19 genotype.
Methods: This retrospective study included patients
who underwent cerebral artery stenting at the First Affiliated Hospital of Chongqing Medical University from January 2019 to February 2023. We divided
them into the aspirin-clopidogrel group and aspirin-ticagrelor group and carefully collected baseline information laboratory data and imaging results
from the patients. The efficacy outcomes were 30 days recurrent stroke, 90 days recurrent stroke, and 180 days recurrent stroke, and the safety outcome was
intracranial hemorrhage. T-tests or Fisher's tests were performed for study outcomes in both groups of patients.
Outcome: A total of 372 patients were included. For
efficacy outcomes, aspirin-ticagrelor was associated with a reduced risk of 180 days recurrent stroke, in patients with CYP2C19 LOF allele and CYP2C19
intermediate metabolic genotype compared with aspirin-clopidogrel. There was no significant difference in the rate of intracranial hemorrhage between patients
with aspirin-clopidogrel and aspirin-ticagrelor, regardless of overall, CYP2C19 LOF allele carriers or CYP2C19 intermediate metabolizer. No significant differences were found between the two on other efficacy and safety outcomes.
Conclusion: A cohort study found that aspirin-ticagrelor
was significantly superior to aspirin-clopidogrel in reducing 180 days recurrent stroke in CYP2C19 LOF allele carriers and CYP2C19 intermediate
metabolizers. There was no significant difference between aspirin-ticagrelor and aspirin-clopidogrel in the risk of intracranial hemorrhage in terms of ICH
rates.
Disclaimer:
Lupin makes no representation or warranty of any kind, expressed or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any
scientific information shared by the HCP on the STAR UPDATE podcast. You should not allow the contents of this to substitute for your own medical judgment, which you should exercise in evaluating the information on this
website.
cerebral artery stenting
Clin Neurol Neurosurg . 2024 Mar 3:239:108229.
Abstract
Objective: First, the efficacy and safety of
aspirin-ticagrelor after cerebral artery stenting in ischemic stroke patients is controversial. Second, there is a gap in the research on guiding two
antiplatelet therapy after stenting based on the CYP2C19 genotype.
Methods: This retrospective study included patients
who underwent cerebral artery stenting at the First Affiliated Hospital of Chongqing Medical University from January 2019 to February 2023. We divided
them into the aspirin-clopidogrel group and aspirin-ticagrelor group and carefully collected baseline information laboratory data and imaging results
from the patients. The efficacy outcomes were 30 days recurrent stroke, 90 days recurrent stroke, and 180 days recurrent stroke, and the safety outcome was
intracranial hemorrhage. T-tests or Fisher's tests were performed for study outcomes in both groups of patients.
Outcome: A total of 372 patients were included. For
efficacy outcomes, aspirin-ticagrelor was associated with a reduced risk of 180 days recurrent stroke, in patients with CYP2C19 LOF allele and CYP2C19
intermediate metabolic genotype compared with aspirin-clopidogrel. There was no significant difference in the rate of intracranial hemorrhage between patients
with aspirin-clopidogrel and aspirin-ticagrelor, regardless of overall, CYP2C19 LOF allele carriers or CYP2C19 intermediate metabolizer. No significant differences were found between the two on other efficacy and safety outcomes.
Conclusion: A cohort study found that aspirin-ticagrelor
was significantly superior to aspirin-clopidogrel in reducing 180 days recurrent stroke in CYP2C19 LOF allele carriers and CYP2C19 intermediate
metabolizers. There was no significant difference between aspirin-ticagrelor and aspirin-clopidogrel in the risk of intracranial hemorrhage in terms of ICH
rates.
Disclaimer:
Lupin makes no representation or warranty of any kind, expressed or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any
scientific information shared by the HCP on the STAR UPDATE podcast. You should not allow the contents of this to substitute for your own medical judgment, which you should exercise in evaluating the information on this
website.
In God we trust